ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced that results were presented from the largest actively monitored, multi-site lead performance evaluation ever conducted for an ICD lead family. The data presented is from an analysis of four prospective studies, all with comprehensive data monitoring on the performance of the Riata® lead family. The analysis concluded that performance and reliability of Riata leads are excellent, based on data collected from more than 680 physicians at more than 370 sites.
